SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

Presented in the tables below is revenue and Segment Adjusted EBITDA by reportable segment:

	For the Three Months Ended March 31, 2022
(in thousands)	Technology Enabled Solutions		Advisory Services
Revenue	$	83,166	$	13,542
Segment Adjusted EBITDA	$	12,370	$	5,323

	For the Three Months Ended March 31, 2021
(in thousands)	Technology Enabled Solutions		Advisory Services
Revenue	$	69,582	$	13,049
Segment Adjusted EBITDA	$	16,307	$	3,338

The following table presents a reconciliation of Segment Adjusted EBITDA to the condensed consolidated U.S. GAAP net income (loss) from operations:

(in thousands)	For the Three Months Ended March 31,
	2022		2021
Technology Enabled Solutions Segment Adjusted EBITDA	$	12,370	$	16,307
Advisory Services Segment Adjusted EBITDA	5,323		3,338
Total	$	17,693	$	19,645
Unallocated(1)	$	(2,377)	$	(2,048)
Adjustments to reconcile to U.S. GAAP net income (loss)
Depreciation and amortization	(8,252)		(7,372)
Interest, net	(3,719)		(5,467)
Income tax provision	676		1,007
Cost of COVID-19(2)	(274)		(1,185)
Sales and use tax	—		(1,498)
Non-cash stock compensation expense	(1,264)		(990)
Transaction related costs	(640)		(1,086)
Acquisition bonus expense	(58)		(192)
Inventory step-up(3)	(1,892)		—
Other(4)	(1,047)		(1,748)
Net income (loss)	$	(1,154)	$	(934)

________________________

(1)Represents certain corporate costs associated with the executive compensation, legal, accounting, finance and other costs not specifically attributable to the segments.

(2)Expenses incurred due to the COVID-19 pandemic are primarily related to higher pricing from vendors due to supply chain disruptions and product shortages and higher employee costs due to hazard pay for our employees. While we had

previously expected that these costs would not be an adjustment in the calculation of Segment Adjusted EBITDA after 2021, the COVID-19 pandemic has not subsided and during 2022, to a lesser extent, we have continued to incur higher product costs due to higher pricing from vendors for certain items (e.g., masks and other similar high demand products). We now expect that these expenses will not be an adjustment in the calculation of Segment Adjusted EBITDA after 2022.

(3)Incremental cost of products associated with the step-up of inventory recognized in purchase accounting for the HealthSmart acquisition.

(4)These adjustments include individual adjustments related to management and board of directors fees and fees associated with obtaining the incremental term loans.